Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Wood, William A  [Clear All Filters]
2024
Grover NS, Hucks G, Riches ML, Ivanova A, Moore DT, Shea TC, Seegars MBeth, Armistead PM, Kasow KA, Beaven AW, et al. Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30 lymphoma: a phase 1 study. Lancet Haematol. 2024.
2023
Sharma A, Logan B, Estrada-Merly N, Lehmann LE, Rangarajan HG, Preussler JM, Troy JD, Akard LP, Bhatt NS, Truong TH, et al. Impact of Public Reporting of Center-Specific Survival Analysis Scores on Patient Volumes at Hematopoietic Cell Transplant Centers. Transplant Cell Ther. 2023.
Wood WA, Dilip D, Derkach A, Grover NS, Elemento O, Levine R, Thanarajasingam G, Batsis JA, Bailey C, Kannappan A, et al. Wearable sensor-based performance status assessment in cancer: A pilot multicenter study from the Alliance for Clinical Trials in Oncology (A19_Pilot2). PLOS Digit Health. 2023;2(1):e0000178.
Barata A, Abrams HR, Meyer CL, Mau L-W, Mattila D, Burns LJ, Ullrich CK, Murthy HS, Wood WA, Petersdorf EW, et al. What Do Patients Think about Palliative Care? A National Survey of Hematopoietic Stem Cell Transplant Recipients. Blood Adv. 2023.
2022
Tokaz MC, Baldomero H, Cowan AJ, Saber W, Greinix H, Koh MBc, Kröger N, Mohty M, Galeano S, Okamoto S, et al. An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Transplant Cell Ther. 2022.
Ullrich CK, Baker KK, Carpenter PA, Flowers ME, Gooley T, Stevens S, Krakow EF, Oshima MU, Salit RB, Vo P, et al. Fatigue in Hematopoietic Cell Transplant Survivors: Correlates, Care Team Communication, and Patient-Identified Mitigation Strategies. Transplant Cell Ther. 2022.
Lew MV, Ren Y, Lowder YP, Siamakpour-Reihani S, Ramalingam S, Romero KM, Thompson JC, Bohannon LM, McIntyre J, Tang H, et al. Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplant Candidates Ages 18-80 Years. Transplant Cell Ther. 2022.
2021
Muhsen IN, Rasheed OW, Habib EA, Alsaad RK, Maghrabi MK, Rahman MA, Sicker D, Wood WA, Beg MS, Sung A, et al. Current status and future perspectives on the Internet of Things in oncology. Hematol Oncol Stem Cell Ther. 2021.
Nakamura ZM, Deal AM, Park EM, Quillen LJ, Chien SA, Stanton KE, McCabe SD, Heiling HM, Wood WA, Shea TC, et al. A randomized double-blind placebo-controlled trial of intravenous thiamine for prevention of delirium following allogeneic hematopoietic stem cell transplantation. J Psychosom Res. 2021;146:110503.
2020
Nakamura ZM, Deal AM, Rosenstein DL, Quillen LJ, Chien SA, Wood WA, Shea TC, Park EM. Cognitive function in patients prior to undergoing allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 2020.
Nakamura ZM, Deal AM, Rosenstein DL, Quillen LJ, Chien SA, Wood WA, Shea TC, Park EM. Design of a Randomized Placebo Controlled Trial of High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation. Contemp Clin Trials. 2020:106076.
Arnold SD, Brazauskas R, He N, Li Y, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, et al. The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization. Biol Blood Marrow Transplant. 2020.
Nazha A, Hu Z-H, Wang T, R Lindsley C, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn J-Y, Cerny J, et al. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients. Biol Blood Marrow Transplant. 2020.
Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, et al. Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.
2018
Davis JMichaud, Ivanova A, Chung Y, J Shaw R, Rao K, Sharf JPtachcinsk, Serody J, Armistead P, Wood WA, Coghill J, et al. Evaluation of a Test Dose Strategy for Pharmacokinetically-guided Busulfan Dosing for Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2018.
Bryant ALeak, Coffman EM, Bullard E, Hirschey R, Bradley J, Stover A, Wood WA, Bennett AV. Experiences of Inpatient Bone Marrow Transplantation Nurses and Providers Using Electronic Symptom Reporting. J Oncol Pract. 2018:JOP1800074.
Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018.
2015
Khera N, Majhail NS, Brazauskas R, Wang Z, He N, Aljurf MD, Akpek G, Atsuta Y, Beattie S, Bredeson CN, et al. Comparison of Characteristics and Outcomes of Trial Participants and Non-participants: Example of Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial. Biol Blood Marrow Transplant. 2015.
2014
Wood WA, Deal AM, Bennett AV, Mitchell S, Abernethy AP, Basch E, Bailey C, Reeve BB. Comparison of Seven-Day and Repeated 24-Hour Recall of Symptoms in the First 100 Days Following Hematopoietic Cell Transplantation. J Pain Symptom Manage. 2014.